Early HIV treatment, combined with therapy to prevent tuberculosis, sharply reduced morbidity in a randomised trial in Côte d’Ivoire.

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers have reported.

The US Food and Drug Administration has approved Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral (ARV) regimen, as a first-line therapy to treat HIV.

Nearly $1.3bn spent on US-funded programmes to promote abstinence and faithfulness in sub-Saharan Africa had no significant impact, an analysis of sexual behaviour data has shown.

Post-operative mortality rates were low among patients infected with HIV who are receiving ART, and those mortality rates were influenced as much by age and poor nutritional status as CD4 cell counts.